BioMed Research International / 2014 / Article / Tab 1

Research Article

Effects of Anti-TNF Alpha Drugs on Disability in Patients with Rheumatoid Arthritis: Long-Term Real-Life Data from the Lorhen Registry

Table 1

Baseline clinical data of the 1033 study patients.

HAQ (SD)
DAS28 (SD)
High773 (74.83%)
Moderate218 (21.1%)
Low15 (1.45%)
Remission15 (1.45%)
Missing12 (1.16%)
Steinbrocker functional classI37 (3.58%)
II706 (68.34%)
III247 (23.91%)
IV37 (3.58%)
Missing6 (0.58%)
Pain visual analogue scale (SD)
Global health assessment (SD)
Swollen joint count (SD)
Tender joint count (SD)
Anti-TNF drugsAdalimumab 305 (29.53%)
Etanercept231 (22.36%)
Infliximab497 (48.11%)
Number of previous DMARDs 167 (6.49%)
2364 (35.24%)
3309 (29.91%)
4172 (16.65%)
5113 (10.94%)

HAQ: Health Assessment Questionnaire; DAS28: 28-joint disease activity score; TNF: tumour necrosis factor; DMARDS: disease modifying antirheumatic drugs; SD: standard deviation.